Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

DealWatch_1200x675

Related Content

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Apr 17 2019

Time For AI To Deliver In Drug Discovery, Says Atomwise CEO

Jun 04 2019

BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT

Jun 04 2019

Vical Faced With Failure of Another Vaccine Trial

Jun 11 2018

Bayer Pays Arvinas $50m To Form Protein Degrader R&D Pact

Jun 05 2019

Spotlight on Q1 Pharma M&A Merry-Go-Round

Jun 05 2019

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

Jun 06 2019

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

May 30 2019

BI Inks Second Obesity Pact With Denmark’s Gubra

May 31 2019

Two Years Of Artificial Intelligence Deals: A Pharma Snapshot

May 30 2019

Santhera Shores Up Finances With Chiesi Deal for Raxone

May 23 2019

Related Companies

Vertex Pharmaceuticals Incorporated

Exonics Therapeutics, Inc.

CRISPR Therapeutics AG

Astellas Gene Therapies

Merck & Co., Inc.

Dana-Farber/Harvard Cancer Center

Achaogen, Inc.

Cipla Limited

Qilu Pharmaceutical Co., Ltd.

Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

Kaken Pharmaceutical Co.,Ltd.

Orca Pharmaceuticals, Ltd.

Inhibrx, Inc.

Chiesi Farmaceutici S.p.A.

Santhera Pharmaceuticals

Arvinas, Inc.

Bayer AG

Roche Holding AG

Eli Lilly and Company

Bristol Myers Squibb Company

Atomwise, Inc.

Boehringer Ingelheim GmbH

Gubra ApS

Additional Topics

Deals Business Strategies Commercial M & A BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window